Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Quality of Life Findings of Adjuvant FOLFOX4 vs. XELOX in Stage III Colon Cancer Patients

  • Youn Jung Choi (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Seun Ja Park (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Moo In Park (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Won Moon (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Sung Eun Kim (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Jae Hyun Kim (Department of Gastroenterology, Kosin University College of Medicine) ;
  • Byung Kwon Ahn (Department of Colorectal Surgery, Kosin University College of Medicine) ;
  • Sung Uhn Baek (Department of Colorectal Surgery, Kosin University College of Medicine) ;
  • Seung Hyun Lee (Department of Colorectal Surgery, Kosin University College of Medicine) ;
  • Seung Hun Lee (Department of Colorectal Surgery, Kosin University College of Medicine)
  • Received : 2017.07.14
  • Accepted : 2017.12.12
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To compare the quality of life (QoL), the convenience of chemotherapy and satisfaction between colon cancer patients treated with FOLFOX4 and XELOX. Methods: The study was conducted in 26 patients with stage III colon cancer. Patients were received FOLFOX4 (n=17) or XELOX (n=9). QoL, convenience, and satisfaction were assessed using the Quality of Life Questionnaire-C30 (QLQ-C30), Quality of Life Questionnaire-Chemotherapy Induced Peripheral neuropathy (QLQ-CIPN) and Functional Assessment of Chronic Illness Therapy Chemotherapy Convenience and Satisfaction Questionnaire (FACIT-CCSQ), respectively. Patients completed questionnaires at baseline, at cycle 4 (C4) and cycle 8 (C8) (FOLFOX4) or at cycle 3 (C3) and cycle 6 (C6) visits (XELOX) and at their final visit. Results: In the QLQ-C30, at the final visit, XELOX patients had better functional scores than FOLFOX4 patients (physical: 85.7 vs.60.4, p=0.03; role: 83.3 vs. 57.5, p=0.04) as well as better symptom scores (constipation: 9.5 vs. 40.4, p=0.01). In CIPN, at the C6/C8 visit, XELOX patients had lower motor scale scores than FOLFOX4 patients (3.8 vs. 21.6, p=0.02). Moreover, at the C6/C8 visit, XELOX was more convenient than FOLFOX4 in FACIT-CCSQ (79.7 vs. 55.5, p=0.04). Male patients were especially likely to consider XELOX to be more convenient (90.0 vs. 55.0, p=0.01) and satisfactory (55.4 vs. 26.2, p=0.03) and fewer concern (91.0 vs. 65.0, p=0.03) than FOLFOX4. XELOX patients spent fewer days on hospital visits at C3/C4, C6/C8 and final visit (2.8 vs. 4.2, p=0.01; 2.7 vs. 4.1, p=0.01; 3.0 vs. 4.5, p=0.01). Conclusion: XELOX may be a better adjuvant chemotherapy choice for patients with colon cancer than FOLFOX4 in terms of QoL, convenience, and satisfaction.

Keywords

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
  2. Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2013, Ministry of Health and Welfare, 2015.
  3. Verhaar S, Vissers PA, Maas H, van de Poll-Franse LV, van Erning FN, Mols F. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry. Eur J Cancer 2015 Jul; 51(10):1263-1273.
  4. NCCN clinical practice guideliens in oncology colon cancer version 1. 2014.
  5. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007 Jun 1;25(16):2198-2204.
  6. Schmoll HJ, Cartwright T, Tabemero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007 Jan 1;25(1):102-109.
  7. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus Oxaliplatin Compared with Fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011 Apr; 10;29(11):1465-1471.
  8. Akhondi-Meybodi M, Akhondi-Meybodi S, Vakili M, Javaheri Z. Quality of life in patients with colorectal cancer in Iran. Arab J Gastroenterol 2016 Sep; 17(3):127-130.
  9. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002 May 97(5):1228-1234.
  10. Conroy T, Hebbar M, Bennouna J, et al. Quality of life findings from a randomized phase-III study of XELOX vs. FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2010 Jan 5;102(1):59-67.
  11. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN 20. Eur J Cancer 2005 May 41(8):1135-1139.
  12. Fayers P, Aaronson N, Bjordal K. EORTC QLQ-C30 scoring manual 1995;11:1-49.
  13. Yost K, Hahn E, Cella D. A new measure of chemotherapy convenience and satisfaction. J Clinic Oncol 23:538s.
  14. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007 Feb; 1;25(4):424-430.
  15. Pelusi J. Capecitabine versus 5-FU in metastatic colorectal cancer considerations for treatment decision-making. Common oncol 2006;3:19-27.
  16. Twelves C, Gollins S, Grieve R, Samuel L. A randomized crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006 Feb; 17(2):239-245.
  17. Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 2013;18(1):54-63.
  18. Bouvier AM, Jooste V, Bonnetain F, Cottet V, Bizollon MH, Bernard MP, Faivre J. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer 2008 Aug 15;113(4):879-886.
  19. Lemmens VE, van Halteren AH, Janssen-Heijnen ML, Vreugdenhil G, Repelaer van Driel OJ, Coebergh JW. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol 2005 May 16(5):767-772.
  20. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006 Sep 1; 24(25):4085-4091.
  21. Mckibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008;13(8):876-885.
  22. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001 Oct; 11;345(15):1091-1097.